Annovis Bio Q3 net loss widens 30% to $9.46 million

PUBT · 1d ago
Annovis Bio Q3 net loss widens 30% to $9.46 million
  • Annovis Bio’s third-quarter 2026 net loss widened 30% year over year to $9.46 million.
  • Research and development expenses more than doubled year over year to $15.78 million.
  • A November public offering raised $21 million in gross proceeds, expected to fund operations through the DUET-AD six-month data readout.
  • Topline DUET-AD results are expected in March 2027, with the six-month treatment period’s final patient visit scheduled for December 31, 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Annovis Bio Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611130800PRIMZONEFULLFEED9876928) on November 13, 2026, and is solely responsible for the information contained therein.